Sonic Incytes Gains FDA Clearance for Velacur ONE™ Ultrasound Elastography Device

Sonic Incytes Medical Corp announced that its Velacur ONE™ ultrasound elastography device has received 510(k) clearance from the U.S. Food and Drug Administration.

Velacur ONE™ is an upgraded version of the original Velacur™, designed for easier handling and enhanced portability, with a streamlined interface to improve the clinician experience. The company plans to leverage this device in both the U.S. and global markets.

Using 3D S-WAVE technology, the device measures liver stiffness, tissue attenuation, and fat content through the Velacur Determined-Fat Fraction algorithm. 

It is intended to assist in managing chronic liver conditions, including metabolic dysfunction–associated steatohepatitis and metabolic dysfunction–associated steatotic liver disease.

Although liver stiffness is commonly used to evaluate fibrosis, it alone is insufficient for monitoring short-term treatment effects in MASH. 

Clinical evidence shows that a 30% or greater reduction in liver fat, as measured by MRI-PDFF, is the most reliable indicator of therapy success.

Velacur ONE™ incorporates the FDA-cleared VDFF algorithm (2024), which correlates strongly with MRI-PDFF (r = 0.85). In studies, it accurately detected fatty liver in 95% of patients with more than 5% MRI-PDFF.